ProSomnus® Sleep Technologies Market Research Report

Background

Overview

ProSomnus® Sleep Technologies is a leading medical technology company specializing in the design, manufacture, and marketing of precision intraoral devices for the treatment of Obstructive Sleep Apnea (OSA). Founded in 2016 and headquartered in Pleasanton, California, the company has developed a range of FDA-cleared, patient-preferred oral appliance therapy devices that offer a non-invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy.

Mission and Vision

ProSomnus is dedicated to providing effective, comfortable, and accessible solutions for individuals suffering from OSA, aiming to improve patient outcomes and quality of life through innovative medical devices.

Primary Area of Focus

The company's primary focus is on developing precision oral appliance therapy devices that reposition and stabilize the jaw during sleep, thereby improving airflow and reducing the symptoms associated with OSA.

Industry Significance

With over 1 billion people worldwide affected by OSA, ProSomnus plays a crucial role in addressing this global health challenge by offering an alternative to traditional CPAP therapy, which is often met with patient non-compliance due to its invasiveness and discomfort.

Key Strategic Focus

Core Objectives

Expand market presence by increasing manufacturing capacity and efficiency.

Enhance product offerings through continuous innovation and technological advancements.

Strengthen relationships with healthcare providers and patients to improve treatment adoption and outcomes.

Areas of Specialization

Design and manufacturing of precision oral appliance therapy devices for OSA treatment.

Utilization of advanced materials and manufacturing techniques to improve device comfort and efficacy.

Key Technologies Utilized

Artificial intelligence-driven medical device design.

3D robotic milling for mass-customized manufacturing.

Primary Markets Targeted

North American market, with plans for international expansion.

Healthcare providers, including sleep dentists, sleep physicians, and primary care providers.

Financials and Funding

Funding History

ProSomnus has undergone multiple funding rounds, including a significant business combination with Lakeshore Acquisition I Corp. in December 2022, which led to the company's public listing on the Nasdaq Capital Market under the ticker symbol "OSA."

Total Funds Raised

The exact total funds raised are not publicly disclosed.

Recent Funding Rounds

December 2022: Completed a business combination with Lakeshore Acquisition I Corp., resulting in a public listing.

Notable Investors

Cetus Capital

Spring Mountain Capital

Intended Utilization of Capital

The capital raised is intended to support the company's expansion plans, including scaling up manufacturing capacity, enhancing technological capabilities, and increasing market penetration.

Pipeline Development

Key Pipeline Candidates

ProSomnus [IA] Sleep and Snore Device

ProSomnus EVO Sleep and Snore Device

Stages of Development

Both devices are FDA-cleared and commercially available, with ongoing enhancements to improve patient comfort and treatment efficacy.

Target Conditions

Obstructive Sleep Apnea

Snoring

Anticipated Milestones

Expansion of manufacturing capacity to meet growing demand.

Introduction of new device models incorporating advanced features.

Technological Platform and Innovation

Proprietary Technologies

Precision intraoral device design tailored to individual patient anatomy.

Advanced materials for enhanced device comfort and durability.

Significant Scientific Methods

Artificial intelligence-assisted design for personalized treatment plans.

3D robotic milling for precise and efficient device manufacturing.

Leadership Team

Executive Profiles

Len Liptak, MBA: Co-Founder and Chief Executive Officer. Former President of MicroDental Laboratories; holds an MBA from the University of Minnesota's Carlson School of Management.

Sung Kim: Co-Founder and Chief Technology Officer. Former Engineering Director at MicroDental Laboratories; holds a B.S. in Mechanical Engineering from California Polytechnic State University.

Jason Orchard: Chief Financial Officer. Managing Director at Spring Mountain Capital; holds a B.S. in Finance from Villanova University and is a Chartered Financial Analyst.

Brian Dow: Chief Financial Officer. Former CFO of Agendia N.V. and Pulse Biosciences; holds a B.S. in Management from the Georgia Institute of Technology.

Board of Directors

Laing F. Rikkers: Executive Chair and Co-Founder. Managing Director of HealthpointCapital LLC; holds a BA from Harvard University and an MA from Teachers College, Columbia University.

Heather Rider: Director and Chair of the Compensation Committee. Board member of Inogen, Inc.; holds a BA from Claremont McKenna College and an MBA from Pepperdine Graziadio Business School.

Steven Pacelli: Director and Chair of the Nominating and Corporate Governance Committee. Executive Vice President and Managing Director of Dexcom Ventures; holds a BS from the University of California, Los Angeles, and a JD from the University of Virginia.

Competitor Profile

Market Insights and Dynamics

The OSA treatment market is experiencing significant growth, driven by increasing awareness of sleep disorders and a rising preference for non-invasive treatment options. The discontinuation of certain CPAP devices has further accelerated the demand for alternative therapies.

Competitor Analysis

CleveMed: Specializes in medical services and devices for portable sleep testing.

Spinamer: Distributes orthopedic medical products in the fields of Trauma, Spine, and CMF.

MediRex: Imports, distributes, and markets medical devices and technologies.

Care and Comfort: Provides medical device solutions.

Strategic Collaborations and Partnerships

ProSomnus has established relationships with healthcare providers, including sleep dentists, sleep physicians, and primary care providers, to expand its market reach and enhance treatment adoption.

Operational Insights

The company differentiates itself through its patient-preferred, non-invasive devices, advanced manufacturing techniques, and commitment to improving patient outcomes, positioning it favorably against competitors.

Strategic Opportunities and Future Directions

Strategic Roadmap

Expansion of Manufacturing Capacity: Opening a new 32,219-square-foot facility in Pleasanton, California, to increase manufacturing capacity and efficiency.

Product Innovation: Continuing to develop and enhance precision oral appliance therapy devices to meet evolving patient needs.

Market Expansion: Strengthening international presence to tap into the global OSA treatment market.

Future Business Directions

ProSomnus aims to solidify its position as a leader in non-CPAP OSA therapy by focusing on technological innovation, expanding its product portfolio, and enhancing patient and provider engagement.